Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Aug;21(4 Headache):973-89.
doi: 10.1212/CON.0000000000000199.

Preventive Migraine Treatment

Stephen D Silberstein
Review

Preventive Migraine Treatment

Stephen D Silberstein. Continuum (Minneap Minn). 2015 Aug.

Abstract

Purpose of review: This article reviews the evidence base for the preventive treatment of migraine.

Recent findings: Evidence-based guidelines for the preventive treatment of migraine have recently been published by the American Academy of Neurology (AAN) and the Canadian Headache Society (CHS), providing valuable guidance for clinicians. Strong evidence exists to support the use of metoprolol, timolol, propranolol, divalproex sodium, sodium valproate, and topiramate for migraine prevention, according to the AAN. Based on best available evidence, adverse event profile, and expert consensus, topiramate, propranolol, nadolol, metoprolol, amitriptyline, gabapentin, candesartan, Petasites (butterbur), riboflavin, coenzyme Q10, and magnesium citrate received a strong recommendation for use from the CHS.

Summary: Migraine preventive drug treatments are underutilized in clinical practice. Principles of preventive treatment are important to improve compliance, minimize side effects, and improve patient outcomes. Choice of preventive treatment of migraine should be based on the presence of comorbid and coexistent illness, patient preference, reproductive potential and planning, and best available evidence.

PubMed Disclaimer

References

    1. Silberstein SD. Migraine. Lancet 2004; 363 (9406): 381– 391. - PubMed
    1. Silberstein SD, Saper JR, Freitag F. Migraine: diagnosis and treatment. In: Silberstein SD, Lipton RB, Dalessio DJ, editors. Wolff’s headache and other head pain. 7th ed New York, NY: Oxford University Press, 2001: 121– 237.
    1. Lipton RB, Silberstein SD. Why study the comorbidity of migraine? Neurology 1994; 44 (10 suppl 7): S4– S5. - PubMed
    1. Silberstein SD, Winner PK, Chmiel JJ. Migraine preventive medication reduces resource utilization. Headache 2003; 43 (3): 171– 178. doi:10.1046/j.1526-4610.2003.03040.x. - PubMed
    1. Silberstein SD, Feliu AL, Rupnow MF, et al. Topiramate in migraine prophylaxis: long-term impact on resource utilization and cost. Headache 2007; 47 (4): 500– 510. doi:10.1111/j.1526-4610.2007.00754.x. - PubMed

MeSH terms